Shared on04 Aug 25Fair value Decreased 5.92%
Despite a marked upgrade in consensus revenue growth forecasts and a notable reduction in future P/E, Moderna's analyst price target has been cut from $47.68 to $44.86. What's in the News Moderna has been dropped from the Russell Top 200 Index and its Value variant, but was simultaneously added to the Russell Midcap Index and Russell Midcap Value Index as part of recent index rebalancing (Key Developments, 2025-06-28/30).
Shared on30 Apr 25Fair value Decreased 3.33%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on23 Apr 25Fair value Decreased 0.44%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on16 Apr 25Fair value Decreased 2.32%
AnalystConsensusTarget has decreased profit margin from 19.3% to 17.3%.
Shared on09 Apr 25Fair value Decreased 2.04%
AnalystConsensusTarget has decreased revenue growth from 0.9% to 0.6%.
Shared on02 Apr 25Fair value Decreased 2.06%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on26 Mar 25Fair value Decreased 2.14%
AnalystConsensusTarget has decreased revenue growth from 1.1% to 0.9%.
Shared on19 Mar 25Fair value Increased 13%
AnalystConsensusTarget has increased revenue growth from 0.9% to 1.1%, increased profit margin from 15.8% to 19.6% and decreased future PE multiple from 49.5x to 39.4x.
Shared on10 Mar 25Fair value Increased 3.23%
AnalystConsensusTarget has decreased revenue growth from 2.3% to 1.7% and decreased shares outstanding growth rate from 0.0% to 0.0%.